MD ( Medical Doctor ) Student, An Najah National University & An Najah National University Teaching Hospital
To identify factors that are associated with poor health-related quality of life in PD patients
Introduction : Parkinson’s disease (PD) is the most common chronic neurodegenerative disorder, it’s a complex disease affecting both motor and non-motor systems in the brain. PD is characterized by motor symptoms including resting tremor, rigidity, bradykinesia and postural instability. However, less is known about non-motor symptoms (NMS), which are very common and often go under recognized and unreported by both patients and clinicians. NMS are comprised of a large range of symptoms : bad sleep quality, fatigue, depression, neuropsychiatric, autonomic, GI and other symptoms. As the disease progresses, the effectiveness of the medication regimen often decreases, daily functioning and social participation become increasingly compromised. NMS are increasingly prevalent over the course of the disease and have become important determinants of patients’ quality of life with PD progression, thus PD has a great impact on the quality of life of the patients.
Objectives : To identify the clinical and demographic factors that are associated with poor health-related quality of life (HRQOL) in patients with PD and how to deal with these factors to improve HRQOL in PD patients.
Methods : A detailed search for researches and studies reporting HRQOL in Parkinson’s disease patients was performed using “PubMed”, and included all the available and updated literature. Manual search for books, documents and manuscripts was also conducted on references of papers reporting reviews.
Results : Non-motor symptoms (NMS) are important features of PD and have become the leading cause of poor HRQOL with disease progression. Depressive symptoms, sleep disorders and increased physical disability were significantly related to lower HRQOL among PD patients.
Conclusion : This study identifies a number of significant associated factors that should be considered when dealing with Parkinson’s disease patients. PD patients with depression, sleep disorders and physical disability reported poor HRQOL.
Abstract: To explore whether self-rated health acts as a potential mediator in the association between functional status and health-related quality of life in Parkinson's disease.Older persons (as most patients with Parkinson's disease are) who reported poor self-rated health compared with those with excellent self-rated health were two-and-a-half times more likely to have experienced a decline in functional ability.Cross-sectional.Socio-demographic and clinical data of the patients (n = 176) were obtained during a structured interview and from medical records. Functional status was measured with the Unified Parkinson's Disease Rating Scale (total score), self-rated health with the first item of the Short-Form 36-item Health Survey Questionnaire and health-related quality of life with the disease-specific questionnaire called the Parkinson's Disease Quality of Life Questionnaire-39. Multiple linear regression analyses and the Sobel test were employed to assess mediation.Self-rated health seems to have a mediating effect on the association between functional status and health-related quality of life. The Sobel test confirmed an indirect effect of functional status via self-rated health on health-related quality of life and showed a statistically significant indirect effect of functional status on health-related quality of life via self-rated health against the direct route without the mediator.Self-rated health partially mediates the deteriorating effect of functional status on health-related quality of life.Supportive and adaptation psychosocial intervention programmes leading to restored self-rated health may enhance the quality of life regardless of disability in Parkinson's disease.
Pub.: 21 Dec '13, Pinned: 31 Jul '17
Abstract: To assess the impact of mild cognitive impairment (MCI) or cognitive decline on health-related quality of life (HR-QOL) in Parkinson's disease (PD).HR-QOL measured by the Parkinson Disease Quality of Life Questionnaire (PDQ-39), MCI according to Movement Disorder Society Task Force criteria and cognitive decline from premorbid baseline were assessed in non-demented PD patients at 6 movement disorder clinics.Among 137 patients, after adjusting for education, gender, disease duration, and Movement Disorder Society Unified Parkinson's Disease Rating Scale total score, MCI was associated with worse scores within the PDQ-39 dimension of communication (p = 0.008). Subjects were divided into tertiles of cognitive decline from premorbid level. Scores in the dimension of stigma were worst in the second tertile of cognitive decline (p = 0.03). MCI was associated with worse social support scores in the second tertile of cognitive decline (p = 0.008).MCI and cognitive decline from premorbid baseline are associated with reduced HR-QOL in communication, stigma, and social support domains. The cognitive decline from premorbid baseline modifies the association between MCI and HR-QOL in PD and knowing both will allow a better appreciation of difficulties patients face in daily life.
Pub.: 19 Jun '13, Pinned: 31 Jul '17
Abstract: The relative impact of motor- and non-motor symptoms on health-related quality of life in early Parkinson's disease is poorly documented.188 patients with incident Parkinson's disease from a population-based study were examined at the time of diagnosis, before initiation of dopaminergic treatment, with follow-up of 166 patients three years later. Health-related quality of life was assessed by the 36-item Short-form Health Survey (SF-36). Motor and non-motor variables were derived from the Unified Parkinson's disease rating scale and other established scales.Multiple regression analyses showed that the non-motor symptoms strongest associated with reduced SF-36 scores at diagnosis and three years later were depression, fatigue and sensory complaints. The motor symptoms most related to impaired SF-36 scores were problems with gait and activities of daily living that cover personal needs. The variance of SF-36 mental summary scores was much better explained by non-motor vs. motor symptoms, both at baseline (R(2) = 0.384 vs. 0.095) and 3 years later (R(2) = 0.441 vs. 0.195). Also SF-36 physical summary scores were better explained by non-motor vs. motor symptoms with R(2) = 0.372 vs. 0.322 at baseline and R(2) = 0.468 vs. 0.315 after 3 years.In early PD, including the phase before dopaminergic treatment is initiated, non-motor symptoms are more important for reduced health-related quality of life than motor symptoms. Fatigue, depression, sensory complaints and gait disturbances emerge as the most relevant symptoms and should be given corresponding attention in the management of patients with early PD.
Pub.: 07 Aug '13, Pinned: 31 Jul '17
Abstract: Improvement of health‐related quality of life (HRQoL) is one of the primary objectives of symptomatic therapies in Parkinson's disease (PD). The aim of this observational study was to investigate possible changes in generic HRQoL in relation to changed PD pharmacotherapy in the clinical setting.A total of 219 outpatients with mild to moderate PD (median H&Y score = 2.0), treated with oral antiparkinsonian medications, were investigated twice with a 6‐month interval. At baseline, PD medication dose was increased for 82 patients for clinical reasons (median increase of 100 mg levodopa equivalent daily dose or 31.9%), whereas medication remained unchanged for 137 patients. Two generic HRQoL questionnaires, EQ‐5D and 15D, were used at baseline and at 6 months, and the baseline and delta HRQoL values were compared between the treatment groups.In the entire sample, the EQ‐VAS score decreased during the study period, indicating a general decline in HRQoL (P = 0.04). There were no differences in the baseline HRQoL values or delta values between the treatment groups as measured with EQ‐5D or 15D (levodopa dose elevated vs dopamine agonist/MAO‐B inhibitor dose elevated vs no change in medication).An approximately 1/3 increase in antiparkinsonian medication dose did not have an impact on generic HRQoL. Disease‐specific QoL may be more sensitive to pharmacotherapy‐related changes in PD.
Pub.: 10 Nov '15, Pinned: 31 Jul '17
Join Sparrho today to stay on top of science
Discover, organise and share research that matters to you